Calidi Biotherapeutics, Inc.

We are a clinical stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses. We are currently developing RedTail, an enveloped vaccinia virus platform designed to deliver genetic medicine to tumor sites, and two proprietary stem cell-based oncolytic virus platforms (SuperNova and NeuroNova). The RedTail platform is expected to open an IND by the end of 2026 with the first compound (CLD-401) delivering IL-15 superagonist to the tumor microenvironment (“TME”).

Current securities

1. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other EventsSep 25, 2026
2. Entry into a Material Definitive Agreement · Other EventsSep 22, 2026
3. 424B5 filingSep 17, 2026
4. 4 filingAug 19, 2026
5. 4 filingAug 19, 2026